P/E ratio for Corcept Therapeutics (CORT)

P/E ratio history for Corcept Therapeutics from 2004 to 2025

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Johnson & Johnson JNJ	20.7	-56.44%	🇺🇸 USA
Novartis NVS	20.5	-57.04%	🇨🇭 Switzerland
Pfizer PFE	19.4	-59.20%	🇺🇸 USA
Eli Lilly LLY	39.8	-16.52%	🇺🇸 USA
Merck MRK	15.7	-67.07%	🇺🇸 USA
Bristol-Myers Squibb BMY	17.1	-64.18%	🇺🇸 USA
MannKind Corp MNKD	26.9	-43.59%	🇺🇸 USA
Esperion Therapeutics ESPR	-3.87	-108.12%	🇺🇸 USA
BioMarin Pharmaceutical BMRN	29.6	-37.90%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.